Topics

Inflazome Appoints Dr Thomas Jung as Chief Medical Officer

02:00 EST 29 Nov 2018 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Industry veteran clinician to lead the clinical development of Inflazome’s pioneering NLRP3 inflammasome inhibitors to treat inflammatory diseases Appointment follows Inflazome’s recent successful...

Other Sources for this Article

Inflazome:
Dr Jeremy Skillington | VP Business Development
E: j.skillington@inflazome.com
T: +353 1 687 5003

Media:
Jonathan Neilan | FTI Consulting
E: jonathan.neilan@fticonsulting.com
T: +353 1 765 0886

Paddy Berkery | FTI Consulting
E: patrick.berkery@fticonsulting.com
T: +353 1 765 0884

NEXT ARTICLE

More From BioPortfolio on "Inflazome Appoints Dr Thomas Jung as Chief Medical Officer"

Quick Search

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...